Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23067161 | 0.76 | DUT (0.31) | — | |
| SCHEMBL10223187 | 0.75 | DUT (0.31) | — | |
| SCHEMBL31294926 | 0.74 | DUT (0.33) | — | |
| SCHEMBL19586459 | 0.73 | SPHK2 (0.31) | — | |
| SCHEMBL1968456 | 0.72 | PDK2 (0.36) | — | |
| SCHEMBL27383375 | 0.72 | DUT (0.33) | — | |
| SCHEMBL5320462 | 0.70 | LMNA (0.33) | — | |
| SCHEMBL6787664 | 0.70 | DUT (0.30) | — | |
| SCHEMBL21155602 | 0.70 | CHRNB2 (0.33) | — | |
| SCHEMBL9059935 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545662-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-11987574-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| EP-4313970-A1 | MK2 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11680056-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11680056-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11680056-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20220402892-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220402892-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2022-12-22 | — | — | US | disclosed |
| WO-2022212489-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987574-B2 | MK2 inhibitors and uses thereof | MKNK2, ENPP2, MAPKAPK2 | NOS3 3656/4885NOS1 3327/4885NOS2 1407/4885 |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | NOS3 3656/4885NOS1 3327/4885NOS2 1407/4885 |
| US-11680056-B2 | MK2 inhibitors and uses thereof | MKNK2, ENPP2, MAPKAPK2 | NOS3 3656/4885NOS1 3327/4885NOS2 1407/4885 |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | NOS3 3656/4885NOS1 3327/4885NOS2 1407/4885 |
| US-20220402892-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | NOS3 3804/4885NOS1 3611/4885NOS2 1811/4885 |
| US-12545662-B2 | MK2 inhibitors and uses thereof | NR3C2, NR2C2, AGTR2 | NOS3 2182/4885NOS1 1789/4885NOS2 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.